Specialty Pharmacy

From the bright lights of Broadway to the darkness of hepatitis C infection, effective new drugs help patient start life anew.

Top stories of the week on Specialty Pharmacy Times.

Global AML market forecast to reach nearly a billion dollars by 2024.

The FDA launcheda cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools.

Ibrutinib is significantly more effective than chlorambucil in chronic lymphocytic leukemia.

Joseph Morse, president and chief operating officer of Therigy, LLC, discusses how specialty pharmacies can meet the reporting requirements required by manufacturers and payers.

An estimated 500,000 incarcerated people in the US are currently infected with hepatitis C.

Researchers evaluate association between psoriasis and cancer.

Urban caregivers on the front lines of fighting HCV.

American adults largely ignorant that insurance covers annual check-ups and there is no cost out-of-pocket associated with it.

An analysis revealed growing evidence of improved access to and affordability of care after the implementation of the Affordable Care Act, but gaps remain, especially for low-income adults.

Taking antiretroviral therapy exactly as prescribed is not only essential for lowering the amount of HIV in an infected individual, but also critical for reducing the risk of transmission.

High blood pressure is an established risk factor for cardiovascular events in patients with diabetes.

A public workshop held by the FDA examined how social media and mobile health may inform medical product safety and efficacy.

Experimental tyrosine kinase inhibitor targets T790M mutation-positive non-small cell lung cancer.

Use of these hepatoprotective agents may reduce the risk of liver damage caused by ingredients in Technivie and Viekira Pak.

Colon cancer in African Americans associated with more aggressive clinical behavior.

Researchers find link between HIV infection and stroke.

Collaboration between caregivers vital to accurately diagnose precursor lesions in inflammatory bowel disease.

Research may offer hope for hepatitis C patients with liver disease.

The FDA has approved insulin glargine injection, a long-acting human insulin analog to improve glycemic control among adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

Insurance coverage and use of care improves among minorities following reform.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses how specialty pharmacies can help patients manage increasing copay costs.

An overview of Daklinza (daclatasvir) for pharmacists.

Long chain fatty acids found to promote the development and propagation of inflammatory cells.

A new report by the Berkeley Research Group provides numbers on Medicare Part B spending by 340B entities, especially for oncology drugs.

The FDA has approved sugammadex (Bridion) to reverse the effects of neuromuscular blockade created by rocuronium bromide and vercuronium bromide.

Panel suggests different regimens for different hepatitis C patient groups.